Recent developments include strategic transactions transferring the POD technology to Lifeward, forming a strategic alliance with Alpha Tau Medical, and clinical development progress in oral insulin and oncology therapies. The company also authorized a stock repurchase plan and appointed a new CFO.

• Oramed transferred its Protein Oral Delivery (POD™) technology to Lifeward, receiving a 49.9% beneficial ownership interest in Lifeward, a medical technology company with established commercial products [N2].
• Oramed formed a strategic alliance with Alpha Tau Medical, investing approximately $38.2 million to acquire about 17% of Alpha Tau's shares, supporting Alpha Tau's clinical-stage oncology therapy development [N3].
• Oramed's new OraTech venture focuses on oral insulin delivery aiming to innovate diabetes care, with clinical trial management services provided under a reimbursement agreement [N5].
• The company authorized a stock repurchase plan as part of its capital management strategy [N8].
• Oramed appointed Avraham Gabay as its new Chief Financial Officer, indicating management changes [N7].
• Alpha Tau is conducting multiple FDA-approved clinical trials for its Alpha DaRT™ platform, including pivotal and pilot studies in various cancers, with some positive interim results reported [S2].
• Oramed's financial results for Q2 2026 showed net income of approximately $78.2 million, driven by financial income related to investments and other income sources [S2].
• Research and development expenses decreased due to the transfer of clinical development activities to OraTech and related reimbursements, while general and administrative expenses increased due to stock-based compensation and professional fees [S2].
• Oramed's liquidity position remains strong with a current ratio of 4.98 and cash ratio of 1.5 as of June 30, 2026 [S2].
• The company continues to face risks related to regulatory approvals, competitive pressures, geopolitical factors, and investment risks in its portfolio companies [S1][S2].
• Oramed's common stock is listed on Nasdaq and the Tel Aviv Stock Exchange, with risks related to maintaining listing standards and market price volatility [S1].
• Recent news highlights Oramed among top biotech gainers and notes ongoing strategic and clinical developments [N1].

Oramed's strategic transactions, including the transfer of its POD™ platform to Lifeward and its significant investment in Alpha Tau Medical, position it to benefit from diversified revenue streams and potential value creation from innovative medical technologies. The ongoing clinical trials of Alpha Tau's Alpha DaRT™ platform, with FDA approvals and designations, represent potential milestones that could enhance the value of Oramed's investment. The company's strong liquidity and reduced research and development expenses following the transfer of clinical activities to OraTech may support operational stability. The authorized stock repurchase plan and recent management appointments may also contribute to shareholder value and operational efficiency.

Oramed faces risks from its dependence on collaborative partners for product development, commercialization, and clinical trial management. The company has a history of net losses and limited direct product revenues, with significant reliance on investment income and licensing agreements. Regulatory approval uncertainties, competitive pressures from larger pharmaceutical companies, and geopolitical risks related to its Israeli operations may adversely affect its business. Investments in portfolio companies like Lifeward, Alpha Tau, and Scilex carry market, clinical, and credit risks, including the possibility of impairment or loss. The company's ability to secure additional financing on acceptable terms is uncertain, which could impact its operational continuity and strategic initiatives.

Oramed's moat is based on its proprietary oral drug delivery technology platform, particularly its Protein Oral Delivery (POD™) system, and its strategic equity stakes in companies like Lifeward and Alpha Tau Medical. The transfer of its oral insulin program to Lifeward aligns it with a commercial-stage medical technology company with established products and recurring revenue streams, potentially providing near-term cash flow and diversified exposure. Its investment in Alpha Tau Medical provides exposure to a novel oncology therapy platform with ongoing clinical trials and regulatory designations. However, the company depends heavily on partnerships for commercialization and clinical development, and faces competition from larger pharmaceutical firms with greater resources. The complexity and regulatory challenges of oral biologic delivery and oncology therapies also contribute to barriers to entry for competitors.

• Dependence on Collaborative Partners: Oramed relies heavily on agreements with partners such as Lifeward and OraTech for development, commercialization, and clinical trial management. Failure to maintain or establish such partnerships could adversely affect its business.
• Regulatory and Clinical Trial Risks: The company faces uncertainties in obtaining regulatory approvals and favorable clinical trial outcomes for its products and those of its investments, which could delay or prevent commercialization.
• Investment and Market Risks: Oramed's significant investments in companies like Alpha Tau and Lifeward expose it to risks related to clinical, regulatory, market volatility, and credit risks, which could materially affect its financial condition.
• Geopolitical and Currency Risks: Operations in Israel expose Oramed to political, economic, and military risks, as well as currency exchange fluctuations that could impact financial results.
• Financial and Liquidity Risks: Oramed has a history of losses and depends on financing through equity offerings and warrant exercises. Availability of financing on acceptable terms is uncertain and could impact operations.
• Stock Market and Listing Risks: The company's stock price is subject to volatility, and failure to meet Nasdaq listing requirements could lead to delisting, affecting liquidity and investor interest.

• Oramed Pharmaceuticals Inc. is a biopharmaceutical company focused on developing orally ingestible drug delivery systems, including oral insulin capsules.
• The company transferred its Protein Oral Delivery (POD™) platform and refined oral insulin program to Lifeward, a commercial-stage medical technology company, in exchange for a 49.9% beneficial ownership interest in Lifeward, which markets products like the ReWalk Personal Exoskeleton and AlterG Anti-Gravity treadmill [N2][S2].
• Oramed entered into a Clinical Trial Management Agreement with OraTech to manage clinical studies of OraTech's investigational oral insulin capsule product, with OraTech reimbursing Oramed for related expenses [S2].
• Oramed has a strategic investment in Alpha Tau Medical Ltd., a clinical-stage oncology company developing the Alpha DaRT™ alpha-radiation cancer therapy platform, holding approximately 17% of Alpha Tau's outstanding shares as of August 2026 [N3][S2].
• Alpha Tau is conducting multiple FDA-approved clinical trials in the U.S. and internationally, including pivotal and pilot studies for various cancers, with some initial positive clinical results reported [S2].
• Oramed's financials as of June 30, 2026, include cash and equivalents of approximately $15.2 million, short-term investments of $0.85 million, current assets of $53.4 million, and current liabilities of $10.7 million, resulting in a current ratio of 4.98 and a cash ratio of 1.5 [S2].
• The company reported net income of approximately $78.2 million for the quarter ended June 30, 2026, with basic EPS of $1.90 and diluted EPS of $1.84 [S2].
• Oramed recognized no revenue in the six months ended June 30, 2026, compared to $2 million in the prior year period related to a Technology License Agreement with Hefei Tianhui Biotech Co., Ltd. [S2].
• Research and development expenses decreased significantly in the six months ended June 30, 2026, primarily due to reimbursements under the Clinical Trial Management Agreement with OraTech and the transfer of related intellectual property [S2].
• General and administrative expenses increased due to stock-based compensation and professional fees [S2].
• Oramed has a history of net losses but has financed operations through private placements, public offerings, and warrant exercises, raising over $255 million net of transaction costs since inception [S2].
• The company faces risks including dependence on collaborative partners for commercialization, competition from larger pharmaceutical companies, regulatory approval uncertainties, reliance on third-party suppliers, and geopolitical risks related to its Israeli operations [S1].
• Oramed's investments in Lifeward, Alpha Tau, Scilex, and other entities expose it to market, clinical, regulatory, and credit risks associated with these investments [S1][S2].
• The company has authorized a stock repurchase plan and appointed a new CFO recently [N8][N7].
• Oramed's common stock is listed on the Nasdaq Capital Market and the Tel Aviv Stock Exchange, with risks related to maintaining listing requirements and market price volatility [S1].